Post-traumatic Arthritis Associated With Joint Injury
Assessment of Biomarkers Associated With Joint Injury and Subsequent Post-Traumatic Arthritis
1 other identifier
observational
20
1 country
1
Brief Summary
Arthritis is the nation's most common cause of disability. An estimated 50 million U.S. adults (about 1 in 5) report doctor-diagnosed arthritis. Twenty three million U.S. adults of working age (18-64 years) have arthritis; and in this age group arthritis-attributable work limitations affect about 1 in 3 people. An estimated 12% of all patients seeking intervention for symptomatic arthritis have an etiology of previous trauma to the involved joint. The purpose of this study is to examine these inflammatory compounds in the joint fluid (synovial fluid), the joint lining (synovium), and in blood among subjects with isolated intra-articular fractures. The hypothesis is that early levels of intra-articular inflammation and markers of joint tissue degeneration following articular fracture in the human knee are predictive of the development of PTA (Post Traumatic Arthritis). Early levels of intra-articular inflammation and markers of joint tissue degeneration identified from human knee joints following articular injury are predictive of the development of PTA in the mouse knee. Samples of blood, urine and synovial fluid will be taken at the spanning frame surgery and only synovial fluid at the ORIF (Open Reduction Internal Fixation)surgery. Two MRIs (Magnetic Resonance Imaging) will be part of this study at 4 weeks and 18 months.Participants will complete a set of questionnaires(KOOS: Knee Injury and Osteoarthritis Outcome Score) at 4 weeks and 18 months.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Oct 2012
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2012
CompletedFirst Submitted
Initial submission to the registry
October 25, 2012
CompletedFirst Posted
Study publicly available on registry
February 15, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2016
CompletedDecember 19, 2016
August 1, 2015
4.1 years
October 25, 2012
December 16, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
Markers of joint tissue degeneration following articular fracture
Tissue samples will be collected at the time of surgery and they will be taken to Duke Basic Science lab where they will be analyzed.
18 months after Injury
Secondary Outcomes (1)
KOOS questionnaire
Participants will complete this questionnaire at the 18 month follow up
Other Outcomes (1)
Change from baseline at 18 months of the extracellular matrix and morphology of knee cartilage using MRI
Between week 2 and 6 and at 18 months after definitive fixation
Study Arms (1)
Single Arm
Interventions
Spanning surgery * A blood sample (32.5 ml) * joint aspirate (removal of synovial fluid) from both knees * urine sample ORIF surgery * Joint aspirate (removal of synovial fluid) from both knees * A blood sample (32.5 ml) * Urine Sample If patients only require one surgery, sample will be collected only once.
Eligibility Criteria
Adults that are at least 18 years old and had a unilateral closed intra articular fracture of the knee that requires surgery.
You may qualify if:
- Subjects will be adult patients (over 18 years old)
- Patients must present with a unilateral closed intra-articular fracture of the knee.
You may not qualify if:
- Pre-existing arthritis in the injured or contra-lateral knee,
- Previous total knee replacement
- Active joint infection
- Pathologic fracture
- Active inflammatory arthritis
- Open fracture of the involved knee
- Contra-lateral knee injury
- HIV infection (if previously known)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Duke Universitylead
- United States Department of Defensecollaborator
Study Sites (1)
Duke University Medical Center
Durham, North Carolina, 27707, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Steven Olson, MD
Duke University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 25, 2012
First Posted
February 15, 2013
Study Start
October 1, 2012
Primary Completion
November 1, 2016
Study Completion
December 1, 2016
Last Updated
December 19, 2016
Record last verified: 2015-08